A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
Randomized, Controlled, Multicenter Phase III Clinical Study Evaluating the Efficacy and Safety of RC48-ADC for the Treatment of Locally Advanced or Metastatic Gastric Cancer With HER2-overexpression
Sponsor: RemeGen Co., Ltd.
Listed as NCT04714190, this PHASE3 trial focuses on Gastric Cancer and HER2 Overexpressing Gastric Carcinoma and remains ongoing. Sponsored by RemeGen Co., Ltd., it has been updated 10 times since 2021, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Feb 2026 — Present [monthly]
Unknown PHASE3
Status: Recruiting → Unknown
-
Sep 2024 — Feb 2026 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Jan 2024 — Jul 2024 [monthly]
Recruiting PHASE3
-
Dec 2023 — Jan 2024 [monthly]
Recruiting PHASE3
▶ Show 5 earlier versions
-
Feb 2022 — Dec 2023 [monthly]
Recruiting PHASE3
-
Nov 2021 — Feb 2022 [monthly]
Recruiting PHASE3
-
Oct 2021 — Nov 2021 [monthly]
Recruiting PHASE3
-
May 2021 — Oct 2021 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Feb 2021 — May 2021 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- RemeGen Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Baoding, China , Beijing, China , Changchun, China , Changsha, China , Chengde, China , Chongqing, China , Fuzhou, China , Guangzhou, China , Hangzhou, China , Harbin, China and 25 more locations